Abstract | BACKGROUND: METHODS: Forty female C57Bl6/N mice were divided into four groups (control, atorvastatin 40 mg/kg for seven days, Proveblue® 10 mg/kg for five days and atorvastatin combined with Proveblue®), infected with Plasmodium berghei ANKA parasites by intraperitoneal inoculation and observed for 45 days. RESULTS: Treatment with atorvastatin alone did not demonstrate an effect significantly different from no treatment (p = 0.0573). All the mice treated by atorvastatin alone died. Treatment with Proveblue® or a combination of Proveblue® and atorvastatin was significantly increased survival of cerebral malaria (p = 0.0011 and 0.0002, respectively). Although there was only one death in the atorvastatin and Proveblue® combination treatment group (10%) versus two deaths (22%) with Proveblue® treatment, the effect on cerebral malaria was not significant (p = 0.283). CONCLUSIONS: The present work demonstrated, for the first time, the high efficacy of Proveblue® in preventing cerebral malaria. Atorvastatin alone or in combination appears to possess limited use for preventing cerebral malaria. Combination of atorvastatin with lower doses of Proveblue® (<10 mg/kg/day) should be evaluated to show potential synergistic effects in cerebral malaria prevention.
|
Authors | Jérome Dormoi, Sébastien Briolant, Camille Desgrouas, Bruno Pradines |
Journal | Malaria journal
(Malar J)
Vol. 12
Pg. 127
(Apr 15 2013)
ISSN: 1475-2875 [Electronic] England |
PMID | 23587099
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antimalarials
- Heptanoic Acids
- Pyrroles
- Atorvastatin
- Methylene Blue
|
Topics |
- Animals
- Antimalarials
(therapeutic use)
- Atorvastatin
- Disease Models, Animal
- Drug Synergism
- Female
- Heptanoic Acids
(therapeutic use)
- Kaplan-Meier Estimate
- Malaria, Cerebral
(drug therapy, epidemiology, mortality, parasitology)
- Methylene Blue
(therapeutic use)
- Mice
- Mice, Inbred C57BL
- Parasitemia
- Pyrroles
(therapeutic use)
|